Why FDA Registration Isn't Enough: The State-by-State Rules That Block 503B Shipments and What Your Clinic Needs to Know

Here's a scenario that catches clinic owners off guard more often than you'd expect:

You find a 503B outsourcing facility with a clean FDA inspection record. They're on the FDA's registered outsourcing facilities list. Their cGMP credentials look solid. You sign a supplier agreement, place your first order of compounded semaglutide or peptide protocols — and the shipment gets blocked.

Not because the pharmacy isn't compliant at the federal level. Because it isn't licensed in your state.

This is the reality of the 503B regulatory landscape in the United States: federal registration is necessary, but it is not sufficient. Every state maintains its own licensing requirements for outsourcing facilities that ship compounded drugs into that state — and those requirements vary dramatically. Some states are relatively aligned with the federal framework. Others impose requirements that amount to near-prohibitions on out-of-state 503B shipments until the facility obtains additional state-level approvals.

If your clinic sources compounded medications from a 503B facility — or is planning to — understanding this patchwork is not optional.

Why States Have Independent Authority Here

The 2013 Drug Quality and Security Act created the 503B outsourcing facility framework and gave FDA primary regulatory authority over these facilities. But the DQSA explicitly preserved state authority over drug compounding. States retain the right to require outsourcing facilities to obtain state-level licenses or registrations before shipping into their jurisdictions.

The FDA has even published guidance recommending that states align their regulations with the federal 503B framework — essentially acknowledging that the patchwork is a problem. Most states have not fully adopted that alignment.

KEY POINT: Federal registration establishes a floor. State licensure controls whether products can legally be shipped into (or within) a state. A 503B facility can be perfectly FDA-compliant and still be blocked from shipping into a state where it lacks the required state permit.

The result is that a clinic in New York is operating under a completely different sourcing reality than a clinic in Texas, which is different again from California, Florida, or Nevada — even if all of them want the same compounded medication from the same national 503B supplier.

State-by-State: How the Requirements Differ

New York

New York imposes some of the most restrictive requirements on outsourcing facilities in the country. The state requires that 503B outsourcing facilities be managed by a New York-licensed pharmacist. Facilities must register as pharmacies if they are dispensing drugs to individuals — even if their primary business is bulk compounding for healthcare providers. An out-of-state 503B that hasn't obtained New York pharmacy licensure and designated a New York-licensed pharmacist-in-charge cannot ship compounded medications into the state.

For clinics in New York sourcing from national 503B pharmacies, this means verifying not just that the pharmacy is FDA-registered, but that it has specifically completed New York's licensing process — which includes different documentation requirements, additional fees, and state inspection coordination.

Texas

Texas classifies 503B outsourcing facilities as a unique subcategory of prescription drug manufacturers, subjecting them to manufacturer-level oversight and reporting requirements. This is a meaningful departure from how most states treat these facilities. Texas requires 503B facilities to hold a specific Texas Outsourcing Facility license from the Texas State Board of Pharmacy, with its own application process, fees, and compliance requirements.

The manufacturer classification also has implications for how Texas interprets the wholesaling prohibition — the federal rule that says 503B products cannot be resold by intermediaries. Texas's framework can create friction with certain pharmacy distribution models that work fine in other states.

California

California requires outsourcing facilities to obtain a separate state license and be concurrently licensed with the California Board of Pharmacy if compounding for non-patient-specific distribution. California's Board of Pharmacy has also been active in tightening its rules around compounding — including recent rulemaking redefining what constitutes 'essentially a copy' of a commercially available drug, which affects which compounded medications can legally be prescribed and dispensed.

For GLP-1 programs in California specifically, the rules around compounded semaglutide and tirzepatide are particularly complex, given both the FDA's evolving position on drug shortage compounding and California's own pharmacy board interpretations.

Florida

Florida has been especially active in legislating around compounded weight-loss drugs specifically. Senate Bill 860 would require that compounded medications for weight loss comply with detailed sourcing and documentation standards — including that the API (active pharmaceutical ingredient) be identical to that used in an FDA-approved drug and sourced from an FDA-registered facility with a clean inspection record within the past two years.

Separately, for non-resident outsourcing facilities (those located outside Florida that ship compounded sterile products into the state), Florida requires a Nonresident Sterile Compounding Permit issued by the Florida Board of Pharmacy. This permit requires its own application, inspection coordination, and ongoing renewal.

Nevada

Nevada's regulatory history illustrates how significant these state-level decisions are. Pharmacies in Nevada were previously prohibited from purchasing product from 503B outsourcing facilities without specific state legislative authorization. The state legislature had to pass SB 161 explicitly allowing pharmacies to purchase from outsourcing facilities — without that legislation, the arrangement would have been prohibited in Nevada regardless of FDA compliance.

This is not a hypothetical. Nevada's situation shows that a fully FDA-compliant 503B facility could be legally blocked from supplying a Nevada pharmacy not because of any federal compliance issue, but simply because the state hadn't legislated permission for the practice.

The Wholesaling Prohibition Adds Another Layer

On top of state licensing requirements, clinics and their pharmacy partners need to understand the federal anti-wholesaling rule under Section 503B. Federal law prohibits 503B outsourcing facilities from selling or transferring their compounded products to any entity other than the facility that compounded them. In practice, this means 503B products must flow directly from the compounding facility to the end healthcare provider — not through intermediary distributors or third-party resellers.

FDA guidance has clarified what this means and doesn't mean:

Permitted: 503B ships directly to a hospital, clinic, physician office, or med spa where the drug will be administered to patients

Permitted: 503B ships to a licensed 503A pharmacy for dispensing to individual patients pursuant to prescriptions

Permitted: Group purchasing organizations can negotiate pricing on behalf of healthcare entities — but the GPO cannot physically hold, transfer, or ship the product

Not permitted: Third-party distributors who purchase from a 503B and resell to clinics

Not permitted: One 503B outsourcing facility purchasing from another and reselling

⚠ WARNING: Some vendors in the wellness space are operating as intermediaries between 503B facilities and clinics — purchasing compounded medications and reselling them. This arrangement may violate the federal anti-wholesaling prohibition. Clinics using such vendors may unknowingly be receiving products from a non-compliant supply chain, which carries enforcement and liability risk.

What Clinics Need to Verify Before Signing With a Pharmacy Partner

Before you finalize a sourcing relationship with a 503B pharmacy — especially for GLP-1s, peptides, or other high-scrutiny compounds — verify the following:

• The pharmacy is on the FDA's registered outsourcing facilities list — confirm this directly at fda.gov, not just from the pharmacy's marketing materials
• The pharmacy holds the specific state license or permit required to ship into your state — ask for copies of current state permits for every state you're in or plan to expand to
• If you're in New York, Texas, California, Florida, or any state with specific outsourcing facility requirements, confirm those specific requirements are met
• Ask for the pharmacy's most recent FDA inspection results — any Form 483 observations or warning letters should be disclosed and explained
• Confirm the pharmacy can provide Certificates of Analysis (COA) for each batch shipped to you — this is evidence that the lot testing requirement is being met
• Understand the pharmacy's recall notification procedures — if a lot is recalled, how will you be notified and what is the process for managing affected product
• Confirm that your sourcing relationship flows directly from the 503B facility to your clinic — not through an intermediary that might violate the wholesaling prohibition

Why This Matters Even More as Peptides Come Back

As the FDA's July 2026 advisory committee process moves forward and compounding pathways for BPC-157, TB-500, CJC-1295, Ipamorelin, and other peptides are restored, the state licensing patchwork will become an even more urgent issue for clinics building peptide programs.

The first pharmacies to get compounding authorization for newly reclassified peptides will be the ones with the broadest state licensing footprints. Clinics that verify their pharmacy partner's state-level compliance before demand peaks will have continuity of supply. Those that don't will discover the state licensing gap when their shipment doesn't arrive.

Wellness MD Group Helps Navigate the Patchwork

Wellness MD Group works with affiliated clinics across multiple states and understands the sourcing compliance requirements that vary by jurisdiction. Part of that work is helping clinics identify pharmacy partners who are not only FDA-registered but licensed in the specific states where those clinics operate — and ensuring that the clinical workflow (medical director engagement, standing orders, patient intake) aligns with the sourcing arrangement.

The regulatory complexity in this space rewards clinics that build their infrastructure deliberately. The state patchwork is real, the consequences of getting it wrong are real, and having a knowledgeable partner who understands both the federal framework and the state-level variations makes a material difference.

Wellness MD Group helps clinics build compliant sourcing and clinical frameworks — including pharmacy partnership vetting, state-specific compliance, and medical director placement. Visit wellnessmdgroup.com.